Not yet FDA approved, retatrutide has led to some of the greatest declines in body weight of any GLP-1 related drug in several large trials.
November 11, 2026 at 5:00 a.m. EST45 minutes ago
(iStock)
The newest GLP-1 drug may change not only appetites, but also knees.
That’s the intriguing implication of the pooled results of two, large-scale, new trials of retatrutide, the most potent GLP-1-agonist drug yet developed.